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Abstract
Background: As genetics technology proceeds, practices of genetic testing have become more heterogeneous:
many different types of tests are finding their way to the public in different settings and for a variety of purposes.
This diversification is relevant to the discourse on ethical, legal and societal issues (ELSI) surrounding genetic
testing, which must evolve to encompass these differences. One important development is the rise of personal
genome testing on the basis of genetic profiling: the testing of multiple genetic variants simultaneously for the
prediction of common multifactorial diseases. Currently, an increasing number of companies are offering personal
genome tests directly to consumers and are spurring ELSI-discussions, which stand in need of clarification. This
paper presents a systematic approach to the ELSI-evaluation of personal genome testing for multifactorial diseases
along the lines of its test characteristics.
Discussion: This paper addresses four test characteristics of personal genome testing: its being a non-targeted type
of testing, its high analytical validity, low clinical validity and problematic clinical utility. These characteristics raise
their own specific ELSI, for example: non-targeted genetic profiling poses serious problems for information provision
and informed consent. Questions about the quantity and quality of the necessary information, as well as about moral
responsibilities with regard to the provision of information are therefore becoming central themes within ELSI-
discussions of personal genome testing. Further, the current low level of clinical validity of genetic profiles raises
questions concerning societal risks and regulatory requirements, whereas simultaneously it causes traditional ELSI-
issues of clinical genetics, such as psychological and health risks, discrimination, and stigmatization, to lose part of
their relevance. Also, classic notions of clinical utility are challenged by the newer notion of ‘personal utility.’
Summary: Consideration of test characteristics is essential to any valuable discourse on the ELSI of personal
genome testing for multifactorial diseases. Four key characteristics of the test - targeted/non-targeted testing,
analytical validity, clinical validity and clinical utility - together determine the applicability and the relevance of ELSI
to specific tests. The paper identifies and discusses four areas of interest for the ELSI-debate on personal genome
testing: informational problems, risks, regulatory issues, and the notion of personal utility.
Background
In discussions on ethical, legal and societal issues (ELSI)
surrounding genetic testing, there is no longer any single
satisfying definition of what constitutes ‘a genetic test’.
Practices of genetic testing are becoming more and more
heterogeneous, not only with regard to the setting and
purpose of testing, but also with regard to the technical
aspects of the tests themselves. Some of these technical
differences between genetic tests are ethically significant
or have implications for legal or societal issues. There-
fore, a clear understanding of the relevant test character-
istics of genetic tests is a necessity for any meaningful
discussion of the ELSI surrounding genetic testing.
Over the last decades, new technologies for genetic
testing have been developed that differ in many respects
from those used in traditional clinical genetic testing for
monogenic diseases. One important development is the
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advent of personal genome testing on the basis of genetic
profiling for the prediction of common multifactorial dis-
eases. Multifactorial diseases, such as cardiovascular dis-
eases [1], age-related macular degeneration [2], type 2
diabetes [3], clinical depression [4], and many types of
cancer [5], are caused by intricate interplays of multiple
genetic factors and non-genetic factors. Through an ana-
lysis of those genetic factors, an individual’s genetic sus-
ceptibility to multifactorial diseases can be determined.
Personal genome testing companies are currently offering
such risk prediction services directly-to-consumer,
thereby raising a range of new ELSI.
With this paper, we aim to clarify the relations between
the more technical characteristics of a genetic test and
the ELSI with which the test is associated. We believe
that a thorough understanding of the technical character-
istics of personal genome tests themselves forms a neces-
sary basis for all further ELSI-discussions in the field.
Our focus on the test characteristics implies that, in this
paper, we will not be able to discuss other aspects that
are relevant to ELSI-discussions, such as characteristics
of the diseases tested for, or the settings in which tests
are offered. Although there are moral differences, for
example, between the offering of personal genome tests
by private companies and the offering of the same tests
by public health care systems, or between testing for dis-
eases for which there are treatment options available and
testing for diseases for which there are no such options,
these differences are not the main subject of this paper.
As personal genome tests are currently offered almost
exclusively in a direct-to-consumer context, we take that
context as the background to our discussion.
First, we will introduce the practice of personal gen-
ome testing. In the second section, we will distinguish
and briefly discuss the following four key test character-
istics of genetic testing: from targeted to non-targeted
testing, analytical validity, clinical validity and clinical
utility. The third section of the paper discloses and dis-
cusses four major areas of implications of these test
characteristics for the ELSI-debate.
Discussion
I Personal genome testing
Personal genome testing for multifactorial diseases is
conducted on the basis of genetic profiling. In a genetic
profile, multiple genetic variants are combined that are
associated with increased or decreased risks for a parti-
cular multifactorial disease. Presently, single nucleotide
polymorphisms (SNPs) are used within genetic profiles
[6]. SNPs are variations of a single nucleotide, the smal-
lest building block of DNA. Most common SNPs that
are known today convey only minor risks [7]. They are
distinguished from mutations that cause monogenic dis-
eases, which are rare but convey large risks.
For almost a decade, companies have been offering
genetic profiles based on SNPs directly to consumers via
the Internet. Initially, personal genome testing compa-
nies marketed single profiles for specific health condi-
tions, or a limited set of profiles for related diseases [8].
Today, companies are offering genome-wide profiling
services that yield a multitude of profiles not only for
common multifactorial diseases, but also for non-medi-
cal traits [9]. In recent years, personal genome testing
companies have been at the centre of an ongoing critical
debate on their ethical, legal and societal issues (ELSI)
[10]. Within the ELSI-debate, personal genome testing
services have been criticized for their lack of clinical
validity [11-13], for being premature [14] or a waste of
private and public money [15,16].
Other direct-to-consumer companies are starting to
offer genetic profiling on the basis of whole-genome
sequencing technology: the analysis of all three billion
base pairs.1 Whether providers make use of genome-
wide SNP-analysis or whole-genome or exome sequen-
cing technology, however, the prediction of common
multifactorial diseases and other complex traits will con-
tinue to be based upon multiple genetic variants, and
thereby upon the construction of genetic profiles. In this
respect, therefore, the scope of this paper is wide and
encompasses all potential forms of personal genome
testing based on genetic profiling: current and future,
commercial and clinical forms, including sequencing
technologies.
II Test characteristics
There are four key test characteristics relevant to the
ELSI-debate to be discussed: from targeted to non-tar-
geted testing, analytical validity, clinical validity and clin-
ical utility (see Table 1).
1. From targeted testing to non-targeted testing
In targeted testing, the patient or consumer is tested for
a single particular disease. Clinical genetic testing is by
definition targeted, because clinical geneticists are scru-
tinizing the genome for risks of a particular monogenic
disease, or, in the process of diagnosis, for one particular
genetic disease to explain clinical symptoms. There are
targeted forms of genetic profiling, where an individual’s
genetic susceptibility to a particular multifactorial dis-
ease is estimated on the basis of a set of genetic variants
across the genome [8]. Personal genome testing compa-
nies have been marketing multi-targeted testing for a
limited range of diseases [9]. Most present-day personal
genome testing companies, however, offer non-targeted
forms of genetic profiling: they genotype millions of
SNPs and construct profiles that convey personal risks
for a large and continuously increasing number of mul-
tifactorial diseases and other genetic traits.2
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1.1 Quantity and complexity of information
Non-targeted forms of personal genome testing offer
unequalled quantities of information on the basis of one
single laboratory assay. There are companies that offer
predictive information about dozens of multifactorial
diseases and other phenotypic traits simultaneously.3
These quantities of information may be too large for
patients or consumers to process. The sheer amount of
information conveyed by personal genome testing poses
problems of information overload as well as feasibility
issues with regard to informed consent requirements.
It is well-known from clinical genetic testing that
genetic information is generally found to be complex.
This is even more true in the context of multifactorial
diseases, for not only are multiple genetic variants, each
with their own effect sizes, involved in the causation of
multifactorial diseases, there are also environmental fac-
tors at play. Multifactorial disease risks are probabilities:
they are relative risks and may diverge only slightly
from average population risks. Empirical studies have
shown that many people find probabilistic information
difficult to interpret [17]. People are inclined to perceive
risks that are only slightly increased or decreased none-
theless in a dichotomous manner, as either ‘high’ risk or
‘low’ risk [18]. They have little prior knowledge of the
genetics of multifactorial diseases [19], and feel incap-
able of understanding complex genetic risk information
[20]. In personal genome testing, for example, consu-
mers may not always understand that negative test
results or lower-than-average risks are no guarantee for
remaining healthy. In non-targeted forms of testing, the
problems of complex information are exacerbated by
the enormous quantity of information.
1.2 Incidental findings
An implication of the current shift from targeted to
non-targeted testing, is that non-targeted testing affects
the ELSI-issue of incidental findings. Incidental findings
are test outcomes that are unintended or unexpected,
for example: SNP-data which are not yet of predictive
ability, but may become so in the future as new SNP-
disease associations are being discovered. In non-
targeted testing, the potential for this type of incidental
test outcomes is much greater than in targeted testing,
simply because it yields a much larger data set, the sig-
nificance of which is not yet fully understood. Conse-
quently, ethical issues that have traditionally been
associated with clinical genetic testing, such as problems
with the disclosure of incidental or future findings and
concurrent psychological risks, may at first glance
become more urgent for non-targeted personal genome
testing. The issue will be further discussed in section
III,1,4.
2. Analytical validity
The analytical validity of a genetic test refers to the
accuracy with which the laboratory assay measures the
genetic variant it is designed to identify. This notion
includes the capacity that the test will be positive if the
genetic variant is present (analytic sensitivity), and nega-
tive if it is absent (analytic specificity) [21]. In the ethical
evaluation of clinical applications of genetic testing, the
analytical validity has traditionally been a primary criter-
ion [22]. It is derived from basic consumer rights: a
genetic test, like any other product, ought to ‘conform
to contract’ and be as described on its labeling.
Some of the early genetic profiling companies were
selling nutritional supplements based on targeted
genetic profiling tests of unproven analytical validity
[23,24]. There has been a sharp critical debate [25,26],
and in many countries, regulatory bodies have become
more alert on direct-to-consumer genetic testing ser-
vices [27,28]. Presently, however, partly as a result of
more responsible conduct of business, analytical validity
is no longer a major topic in the ethical debate on per-
sonal genome testing. The new generation of personal
genome testing companies is analytically reliable,4 such
that most current “genomic assays have high sensitivity
and specificity for measured genetic variants” [29]. The
Table 1 Test characteristics of personal genome testing and their implications for the discourse on ELSI
Test characteristic Implications ELSI
From targeted to non-targeted
testing
Quantity and complexity of information The information problem
- Informed consent
- Information provision (pre-test and post-test)
- Informational updates
- Incidental findings
Analytical validity High analytical validity Regulatory issues
Clinical validity Generally poor clinical validity (validity varies per disease
tested for)
- Psychological risks, health risks and societal
risks
- Regulatory issues
Clinical utility Generally poor clinical utility (utility varies per disease tested
for)
- Personal perspectives on utility
- Changing interpretations (fluidity of
information)
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industry strives for transparency and truth-in-advertis-
ing, and discloses detailed information on the technolo-
gies used for their laboratory assays.5 Although the
policy-making process is still ongoing, many companies
have responded with improved analytical validity.
3. Clinical validity
Whereas analytical validity refers to the quality of the
laboratory assay, clinical validity is a criterion of the
interpretation of assay results, a criterion of the test [30].
Clinical validity is measured by the predictive ability or
discriminative power of the genetic variant: its ability to
classify individuals as those who will develop the disease
and those who will not [21]. Since the effects of SNPs on
disease risks are so small, most current personal genome
tests lack that discriminative power. By far the largest
proportion of patients or consumers will demonstrate
personal risks for multifactorial diseases that approxi-
mate the average population risk: these risks will prove to
be only slightly lower or slightly higher [31]. A genetic
profile that yields individual outcomes between 14% and
21% for major depressive disorder cannot be clinically
meaningful when the average population risk is 17%.
There will only be few consumers with absolute risks
that diverge sufficiently from the average population risk
to be clinically significant. Therefore, in contrast to that
of clinical genetic testing for monogenic diseases, the
clinical validity of genetic profiling for multifactorial dis-
eases for the purposes of individual disease risk predic-
tion, so far, has remained rather limited.
Statistical studies are finding that the addition of rela-
tively significant SNPs to conventional risk models does
not always improve their discriminatory power, for exam-
ple: genetic information has not been capable of improv-
ing traditional prediction models for type 2 diabetes
based on phenotypic risk factors and family history [32].6
Genetic profiles are expected to gain some clinical valid-
ity in the future as they are refined and expanded to
include more SNPs or other genetic variants, especially
as they may become based on sequencing technologies
[33]. Further, with the inclusion of environmental factors
into risk profiles for multifactorial diseases, their clinical
validity may gradually increase even further.
4. Clinical utility
In recent years, there have been conceptual discussions
of the criterion of clinical utility, which has been widely
used for the (ethical) evaluation of genetic screening
programmes [34]. Roughly, there are three perspectives
on utility: the public health perspective, the clinical per-
spective and, finally, the personal perspective [35],
which will be discussed in the next section. Within the
public health perspective, in order to have utility, a
genetic test must improve health outcomes in terms of
morbidity or mortality on the societal level, be cost-
effective, and produce benefits that outweigh the risks
[36]. The principle of clinical utility requires test results
to provide patients with ‘actionable options’ for preven-
tion or treatment that are accessible and safe and that
have been proven to be effective. From the clinical per-
spective, genetic information must alter clinical manage-
ment, influence therapeutic decision-making, or lead to
better prediction models [37]. Current personal genome
testing for multifactorial diseases is not likely to pass
the test in either perspective.
Within a clinical perspective, genetic profiling for, for
example, type 2 diabetes may become clinically valid in
the future, and thus capable of disclosing informative and
reliable risks, but it may not necessarily become clinically
useful. For it is not always clear what to do with a slightly
increased personal risk of developing type 2 diabetes, or
whether, say, a 28% absolute chance is a sufficient reason
to take preventative action or to alter clinical manage-
ment. Within a public health perspective, there are estab-
lished preventive measures available for type 2 diabetes,
such as weight loss, exercise, and smoking cessation.
These measures are inexpensive, harmless and, in fact,
beneficial to the whole of the population. Since it would
be worthwhile to prescribe these measures to both high-
risk and low-risk individuals for type 2 diabetes, however,
the usefulness of the genetic test is minimal. As long as
personal genome tests continue to be of minimal clinical
utility, they will not find their way into the clinic.
4.1 A personal perspective on utility
The third and personal perspective on clinical utility
takes a broader and more subjective view, for it is
defined by patients or consumers themselves. It allows
for non-medical, particularly psychological motivations
for genetic testing, such as solace [38], family planning
or preparation for the future [29]. In clinical genetics,
non-medical motivations are often part of the counsel-
ing and decision-making processes, paradigmatically in
genetic testing for Huntington’s disease, for which there
are no preventative or therapy options available. Such
testing has ‘clinical utility’ from a personal point of
view: test outcomes may offer either reassurance or cer-
tainty, and, subsequently, the psychological benefits of
‘knowing’ and the ability to make important life deci-
sions, including, importantly, reproductive decisions. In
the context of new technologies for genetic profiling,
critics have proposed to broaden the concept of ‘perso-
nal utility’ much further, so as to include the value of
‘information per se’ [35], the desire to be reassured, and
something like the fun aspect or the entertainment
value of knowing about one’s genes.
4.2 Changing interpretations
The clinical utility of genetic profiles is affected by a
further test characteristic, namely that of changing assay
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interpretations. As genetics research proceeds, more and
more gene-disease associations are discovered. Newly
found genetic variants are included in ever more
extended genetic profiles. As personal genome testing
companies offer updates of their profiles, however, the
companies’ test outcomes are therewith subject to
change over time [39]. On the basis of the same biologi-
cal sample and the same laboratory assay, companies
may present diverging, and even contradictory, test out-
comes over time. A consumer reports:
“When I had my genome scanned a year and a half
ago, using deCODEme’s direct-to-consumer genotyp-
ing service, the results suggested my lifetime risk of
having a heart attack was slightly higher than usual, at
1.12 times the average. When I logged on to my profile
again today, though, I discovered that my chances of
developing the same condition now appear to have
shot up: my relative risk is now 1.28, giving me a 62.7
lifetime risk of having a heart attack. [....] What has
changed, however, is the data that the company uses
to calculate genetic risk. In May, deCODEme added
six new genetic variations to its algorithm for assessing
its customers’ risk of having a heart attack, on the
back of new research [40].”
The probability of receiving contradictory results over
time is quite high. A modeling study on genetic profiling
for type 2 diabetes has shown that the update from one
relatively strongly predictive SNP by an additional 17
less predictive SNPs, causes 34% of the study’s popula-
tion to switch risk categories either from above average
risk to below average risk or vice versa [41]. Due to
changing interpretations, personal genome tests yield
fluid test results.7
III. Implications for the ELSI debate
In this section, the implications of the test characteris-
tics of personal genome tests for the discourse on ELSI
will be discussed. As shown in section II, 3, the test
characteristic of analytical validity is no longer a topic of
major concern in the ELSI-debate since the advent of a
new generation of personal genome testing services.
Therefore, it will not be discussed any further. The
three remaining test characteristics (together) do lead to
ELSI that are of importance to the current debate on
personal genome testing in a direct-to-consumer con-
text: informational problems, risks, regulatory issues and
notions of utility.
1. Non-targeted testing: The information problem
The most important ELSI-issues in personal genome
testing are related to information. Within the ELSI-
debate, it has already been argued that priority ought to
be given to informational problems; critics have stated,
for instance, that both public and professional institu-
tions ought to take up the responsibility to inform the
general public, to raise awareness of the risks of direct-
to-consumer genetic testing [42], and to develop reliable
information sources for consumers as well as physicians
[43]. The previous section has brought to light a subset
of test characteristics that together lead to the problem
of information within non-targeted genetic profiling:
quantity, complexity, and fluidity of information. The
informational problem is associated with the practice of
non-targeted genetic profiling itself, whether within or
outside the clinic, now or in the future.8
Discussions of the difficulties surrounding the provi-
sion of genetic information are not new: in clinical
genetic testing, patients are routinely offered extensive
genetic counseling prior to consenting to undergo
genetic testing. During counseling sessions, the patient
receives detailed information about the disease, the
genetic component thereof, the testing procedure, possi-
ble outcomes, therapeutic options, implications for
reproductive choices and possibilities, consequences for
the family, the communication of possible risks to rela-
tives, social implications, privacy issues, potential
adverse effects on employment and insurance, etc. [44].
Ideally, a well-considered decision is made by the
patient and informed consent is obtained on the basis of
accurate and detailed information.
In targeted genetic profiling, it will not necessarily be
difficult to meet these widely endorsed high standards
for informed consent: in all likelihood, the genetic coun-
selor will be able to deal with most relevant aspects of
genetic testing for any single multifactorial disease
within the scope of a few counseling sessions. Non-tar-
geted genetic profiling, however, poses the problem of
exceptional quantities of information on dozens to over
a hundred different diseases. It will be very arduous, if
not impossible, to inform patients or consumers before-
hand in detail on all relevant aspects for so many dis-
eases without inducing information overload and
therewith foregoing the actual aim of informed consent
[45].
The information problem will be even greater for
whole-genome sequencing, which will reveal not only
SNPs that are weakly associated with risks of multifac-
torial diseases, but also highly predictive mutations that
cause monogenic diseases. As a consequence, the direct-
to-consumer availability of whole-genome sequencing
services might imply serious psychological risks as well
as health risks, and thus will have important ELSI-impli-
cations of its own. These issues, albeit pressing, are
beyond the scope of this paper, which focuses specifi-
cally on personal genome testing in the context of mul-
tifactorial diseases.
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1.1 Informed consent
Informed consent is intended to protect individuals
against unwanted procedures and to acknowledge the
individual’s capability to decide for himself or herself
whether or not to receive information with regard to
their health status or to undergo a physical examination
or intervention. Informed consent “allows individuals to
exercise their fundamental right to decide whether and
how their body, body parts and associated data will be
used” [46]. The right to respect for autonomous deci-
sion-making and the protection against misuse of
human bodies are among the pillars of health care ethics
[47] which hardly any of us will desire to give up. How-
ever, the feasibility of informed consent requirements is
seriously threatened by the informational problems asso-
ciated with personal genome testing.
There are three basic responses to the problem of
informed consent: first, it could be argued that, if fully
specific informed consent is not possible for non-tar-
geted genetic profiling, these services ought not to be
made available, at least not in any non-supervised,
direct-to-consumer fashion [13]. Second, if it is
acknowledged that full and accurate information is not
always possible or even available in the genetics of mul-
tifactorial diseases, it could be concluded that the ideal
of informed consent has become outdated and (for that
domain of genetics) had best be abandoned altogether.
Third, if it is accepted that the provision of information
will necessarily be incomplete, it could be claimed that
the procedure ought to focus on the information that is
most necessary and indispensable for consumers to give
valid consent and to effectively prepare themselves for
personal genome testing. Versions of the third ethical
position have already been proposed [48-50]: they are to
serve the value of consumer autonomy, for they preserve
access to personal genome testing and allow for liberty
of choice. At the same time, they recognize that patients
have a need for and a right to information - for without
adequate information, freedom of choice is meaningless.
We also find the third position more convincing than
the other two, and believe that informed consent is both
possible and required for direct-to-consumer personal
genome testing. Further discussion and research are
needed to determine exactly what (selection of) informa-
tion (and to what level of detail) is most crucial for valid
informed consent. For example, patients or consumers
may need to be informed beforehand in general terms
about changing interpretations as a consequence of
ongoing genetics research. Also, they may need to be
made aware of ELSI-related differences between diseases
or types of diseases. Finally, for instance, patients or con-
sumers may need to be given the opportunity to decide in
advance what kinds of genetic information they do and do
not wish to receive as part of an informed consent process.
1.2 Information provision: pre-test and post-test
In personal genome testing for multifactorial diseases,
consumers or patients are confronted with a double
uncertainty: genetic risks in themselves are probabilistic,
and the clinical validity and utility of these risks are
doubtful. Patients or consumers are likely to experience
difficulties not only during the process of informed con-
sent, but also afterwards, when they receive and inter-
pret their test outcomes. In recent years, there has been
disagreement over the way in which test results ought
to be provided in personal genome testing, particularly
over the question whether face-to-face discussions with
a genetic counselor are deemed necessary. Some have
stated that all genetic testing ought to be accompanied
by genetic counseling [51-54], in order to warrant accu-
rate interpretations of test results.9 Live discussions with
genetic counselors are required in complex cases, such
as incidental findings. Others however have argued that
“in the context of possible widespread introduction of
genetic screening for common diseases, genetic counsel-
ing should be concentrated on those conditions that
threaten life or have a serious impact on the ability to
live life fully” [55]. From the second position it follows
that the need for face-to-face counseling does not apply
to present-day personal genome testing for multifactor-
ial diseases, for serious psychological impact is not to be
expected (see section III, 2). This more liberal position,
which we believe is preferable to the more stringent
position, would allow providers of personal genome test-
ing services to suffice with the provision of adequate
written information, both pre-test and post-test.
1.3 Information updates
Most companies or institutions tend to retain biological
samples or genetic data sets from their clients or patients
[56]. In the future, as new discoveries will occur within
the field of human genetics, new and important disease
risk information could potentially be deduced from the
original data. It is still a matter for debate whether com-
panies or institutions have a moral or legal duty to gather
that information and to re-contact their clients or
patients. Roughly, there are three possible stances: firstly,
companies or physicians do have such moral duty and
ought, for instance, to provide regular updates on the
clinical interpretation of purchased genetic data sets. Sec-
ondly, consumers or patients may prefer to decide indivi-
dually whether or not they wish to be contacted in the
future, and on what conditions. They could be given the
opportunity beforehand to express their wishes with
regard to future findings. Thirdly, it is a moral responsi-
bility of patients themselves to become or to remain
informed on scientific proceedings or to re-contact their
companies or physicians if they wish to obtain updated
information. The distribution of moral responsibilities,
we believe, may depend largely on contextual variables,
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discussion of which, however, is beyond the scope of this
article. On a general level, we think that there are differ-
ences in the extent of moral responsibility between com-
panies on the one hand and physicians or health care
institutions on the other hand, since the latter can be
said to have a stronger professional duty than the former
to provide their patients with medical care and follow-up.
1.4 Incidental findings
In section II, 2, the increased potential for incidental
findings has been mentioned for non-targeted personal
genome testing. However, it could contrarily be argued
that, in non-targeted testing, no finding is incidental.
The aim of non-targeted testing is to convey a lot of
information on the basis of one biological sample. Perso-
nal genome tests are marketed and presented to the
public to include a wide variety of SNP-trait and SNP-
disease associations, and companies tend to update risks
and include more diseases as soon as new SNP-disease
associations have been validated.10 If the aim is to look
for everything, the notion of an incidental finding loses
its original meaning. Keeping the patient or consumer
perspective in mind, however, it is important to note
that they may not always be prepared for finding every-
thing: they may still be surprised by some of the (for
them) incidental findings. It could be argued that they
ought to be made aware of a right not to know certain
(types of) information, as part of an informed consent
process.
2. Clinical validity and utility: Psychological risks, health
risks and societal risks
Theoretically, there are three types of risks to be expected
from personal genome testing, as a result of its limited
clinical validity: psychological risks, health risks, and socie-
tal risks. First, the complexity of genetic information
together with the limited predictive ability of the tests
themselves, render personal genome testing susceptible to
misunderstanding and misinterpretation. Consumers
could feel worried about overestimated disease risks and
could suffer from undue anxiety. Critics have worried that
a class of ‘worried well’ might come into being [57-59],
especially since some present-day personal genome testing
companies tend to exaggerate the clinical validity of their
services.
On the other hand, we believe that adverse psycholo-
gical effects that are well-known from clinical genetic
testing, such as emotional distress, depression or survi-
vor guilt as a result of test outcomes, are not to be
expected from genetic profiling to the same extent [60].
As test outcomes for multifactorial diseases lack clinical
validity, they are much more likely to lead to epistemic
uncertainty than to the major psychological impact
known from clinical genetics. Moreover, empirical
research has shown that even genetic testing of high
clinical validity, such as for hereditary breast or colorec-
tal cancer syndromes, leads to much less psychological
harm than traditionally thought [61]. The provision of
genetic information of more limited clinical validity,
such as in type 2 diabetes, appears not to adversely
affect individuals at all [62,63]. Thus, the psychological
risks involved in personal genome testing are likely to
be overestimated. At the same time, however, we
acknowledge that the potential for misinterpretation and
misunderstanding of complex genetic information can-
not be stressed too frequently.
Secondly, it is frequently argued that there are health
risks implied in personal genome testing for multifactor-
ial diseases [12][25]. False reassurance on the basis of
testing of limited clinical validity is thought to lead
patients or consumers to adopt unhealthier lifestyles, to
omit standard preventative measures, or to forego regu-
lar screening, thus causing harm to their health. The fol-
lowing example constitutes a worst-case scenario: there
are companies that analyze sets of SNPs for calculating
the risk of colorectal cancer.11 These SNPs are asso-
ciated with common, non-hereditary forms of colorectal
cancer and are very weak risk factors of limited clinical
validity. The genetic profile offered does not include
highly penetrant mutations involved in the causation of
5-10% of cases of monogenic hereditary colorectal can-
cer syndromes [64]. Hypothetically, consumers from
high-risk families could feel reassured on the basis of a
few negative SNPs of limited clinical validity, whereas
their genomes have not been analyzed for other, higher-
risk mutations. In reality, however, we expect that at-
risk consumers are likely to present themselves at clini-
cal genetics centers for testing, so these cases will be
rare in a direct-to-consumer context. At present, there
is no empirical evidence to back up the fear of false
reassurance. There are indications that the impact upon
lifestyle is minimal in most consumers of personal gen-
ome testing [63]. Thus, we believe that fears of health
risks may be overstated.
Finally, there are at least two perceived societal risks
involved in personal genome testing of low clinical valid-
ity: indirect economic risks, and loss of public confidence
in genetics research and applications. Firstly, on the basis
of personal genome test results, consumers may turn to
their physicians for advice, follow-up research or medica-
tion. As the clinical validity of test results are uncertain,
most of the follow-up will be unnecessary while it does
drive up the costs of public health care [15][65]. Empiri-
cal studies suggest that consumers are indeed likely to
consult their physicians for help with the interpretation
of tests results obtained from personal genome testing
companies [16][20]. Thus, private spending on direct-to-
consumer personal genome testing may ultimately lead
to higher collective costs of public health care. Secondly,
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it has been pointed out that the commercial availability of
personal genome testing before it has attained sufficient
levels of clinical validity and utility, may undermine pub-
lic trust in genetics medicine and research [13][66]. It is
argued that present-day genetic profiles are of such lim-
ited clinical validity that consumers will be disillusioned
with their purchase, which could deprive genetics
research of its chances to flourish. Changing interpreta-
tions may pose further threats to the public perception of
clinical utility of personal genetic information [67].
Although personal genome testing implies its own
potential societal risks, there is at least one such risk
that has always been paramount to the ELSI-debate on
clinical genetic testing, but that lacks ground in the con-
text of genetic profiling for multifactorial diseases: the
risk of discrimination or stigmatization. Genetic profiles
of limited clinical validity will not be of interest to
insurance companies or employers due to their limited
utility for the purposes of risk stratification [68]. Indeed,
genetics professionals today generally consider the risk
of genetic discrimination to be very low [69].12 In spite
of widespread concern among ELSI-researchers, we
therefore think that the fears of discrimination and stig-
matization are not justified in the context of present-day
personal genome testing.13 We agree, however, that the
risks of discrimination and stigmatization will again be
of relevance to the ELSI-debate if personal genome test-
ing gains sufficient clinical validity and becomes capable
of reliably discriminating between individuals with high
and low risks of developing multifactorial diseases.
3. Clinical validity: Regulatory issues
A third main ELSI associated with personal genome
testing for multifactorial diseases is the legal and societal
issue of regulation. The regulatory issue entails the ethi-
cal question whether it is morally justifiable to offer
genetic tests of limited clinical validity and utility to the
public, and if so, on what conditions. Within the regula-
tory debate, there are roughly two perspectives: the first
emphasizes the value of protection and the second that
of autonomy and consumer choice. From within the
first perspective, there have been calls for enhanced gov-
ernment oversight and regulation [70-72], whereas the
second perspective prioritizes respect for consumer lib-
erty, to be complemented with governmental efforts to
provide reliable information and to promote self-regula-
tion of the market [73,74].
Within the first perspective, there are two separate
and sometimes conflated positions: the position that
genetic tests of unclear informational significance ought
not to be offered direct-to-consumer, and the position
that genetic testing in general must not be made avail-
able commercially (see Table 2). The first position pre-
supposes that personal genome tests are of inferior
clinical validity, and that they cannot be said to yield
medical information at all. Personal genome tests are
considered to be flawed as medical tests, or even as
informational products [11], and thus, they ought not be
put onto the market [13]. Contrarily, the second posi-
tion presupposes that part of the information offered by
direct-to-consumer personal genome testing companies
may indeed be or become of clinical significance [25]
[75]. Analogous to clinical genetic testing, clinically valid
direct-to-consumer personal genome testing is not with-
out risk, it is claimed (see also section III,2). Therefore,
personal genome testing ought not to be made available
commercially, outside of the clinic. Prior consultation of
a physician or a genetic counselor is or should be man-
dated in all genetic testing, in order to ensure adequate
patient protection.
Within the second perspective, it can be maintained
either that the risks of current direct-to-consumer per-
sonal genome testing of low clinical validity are not suf-
ficiently serious to justify any infliction upon consumer
autonomy and liberty of choice, or that the benefits of
testing outweigh the risks (see Table 2). Either way, the
second perspective states that patients or consumers
ought to be allowed to make their own choices on the
health care market, and that the availability of personal
genome tests ought not to be restricted through govern-
ment intervention. This means that even if there are
psychological or health risks involved in personal gen-
ome testing for multifactorial diseases, competent con-
sumers ought to be allowed, on the basis of adequate
information, to make autonomous decisions regarding
whether or not to undergo such testing.
We endorse the more liberal position within the regu-
latory debate, because we believe that the right to liberty
of choice, where possible, must be respected in consent-
ing adults. As discussed above, given the complexity and
the quantity of the information, it will not always be
easy for consumers to make rational and well-consid-
ered decisions with regard to the purchase of direct-to-
consumer personal genome testing. We therefore believe
that there are limits to the liberal position: providers
may be required to make an extra effort to help their
customers overcome the information problem.
4. Clinical utility: A personal approach to utility
Some groups of consumers appear to be attracted to
personal genome testing for multifactorial diseases:
some of the first empirical studies suggest that consu-
mer interest is rather high and growing [20][76]. Thus,
it seems that personal genome tests as consumer pro-
ducts have some sort of value. Over the last few years,
the concept of clinical utility has been widened in order
to account for that value. Notions of personal utility
have been explored [35], and suggested in support of
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liberal attitudes towards direct-to-consumer personal
genome testing [77].
The notion of personal utility is not unequivocal: it
refers to different kinds of values, some more weighty than
others. Whereas personal utility can refer to values such as
a desire for certainty, an opportunity to prepare for the
future, or possibilities for reproductive decision-making
(see section I,4,1), there are also more ‘frivolous’ interpre-
tations that align with the marketing rhetoric used by pre-
sent-day personal genome testing companies. Apart from
medical information, these companies offer genetic infor-
mation about ancestry and other non-medical phenotypic
traits, such as ear wax type, musculature type, eye colour
or alcohol flush reaction. Personal genome testing services
have been labelled ‘recreational genomics’ [16][78], and
have been compared with astrology [78]. Not only are per-
sonal genetic tests marketed as a form of entertainment or
even as a hobby [79], they are also presented as “a ticket
to some sort of insight that amuses, edifies or helps one
find one’s place in society” [80]. On company websites, cli-
ents report having found out ‘who they really are.’14 Some
companies stimulate consumers to share and compare
their genetic make-up and to form online social networks
around traits or medical conditions.
Critics have warned against the emphasis on the
recreational value of personal genome testing: genetic
tests cannot and must not be said to be purely (or even
primarily) recreational when in fact they inform on
(among other things) risks for serious medical condi-
tions [81]. They have also questioned the capacities of
consumers to assess personal utility. Consumers who
believe that information obtained from personal genome
testing is useful for them might have poor understand-
ing and false expectations of the significance and the
utility of that information [82]. Consumers may stop to
perceive personal utility after having been informed
thoroughly on the benefits and risks of non-targeted
forms of genetic profiling. Studies have found that many
people indeed tend to lose interest in genetic testing
after having been informed about the limitations thereof
[83-85].15 Thus, the notion of personal utility of such
tests could be questioned, as it may be based not so
much upon considered valuations of consumers, but
rather upon misconceptions that could partly be
rebutted through the provision of information. In the
absence of any clinical validity, we think that personal
approaches to clinical utility, especially in the context of
testing for disease risks, are unjustified.
On the other hand, in the presence of sufficient, rea-
sonable or increasing levels of clinical validity, we
believe that a personal approach toward utility may
indeed be sensible: consumers may wish to decide for
themselves whether informative non-targeted genetic
profiling is valuable for them, and in what way. The
high standards of clinical utility that are used within
public health care evaluations need not be identical to
the standards applicable to individual consumer valua-
tions of personal utility. For example, consumers may
find personal utility in knowing their genetic risk for
Alzheimer’s disease, despite the absence of preventive
options. This issue deserves further elaboration, which is
beyond the scope of the present article.
Summary
For a well-informed and meaningful discourse on the
ethical, legal and societal issues (ELSI) of present-day
personal genome testing for multifactorial diseases, it is
important to clarify the relevant test characteristics of
personal genome tests. Test characteristics that are most
essential to the current ELSI-debate are the following:
non-targeted testing, high analytical validity, limited
clinical validity, debatable clinical or personal utility, and
the quantity, complexity and fluidity of the generated
personal genetic risk information.
Non-targeted personal genome testing yields a vast
amount of information that is complex and probabilistic,
sometimes for a dozen to over a hundred multifactorial
diseases simultaneously. Further, test outcomes may
change over time as providers include additional genetic
variants in their algorithms. Quantity, complexity, and
fluidity of genetic information together pose urgent pro-
blems with regard to the provision of information and
informed consent. Providers of personal genome testing
are facing these informational problems at several
Table 2 Four positions on clinical validity and regulatory requirements
Does personal genome testing have clinical validity?
Yes (or some) No (or not sufficiently)
Does personal
genome testing
require regulation?
Yes Because of potentially adverse health impact, and
psychological and societal risks, personal genome testing
ought to be made available only under medical
supervision
Because of the risks of over-interpretation and subsequent
health risks, personal genome testing ought not to be
allowed on the market
No The risks are only minor, whereas access to (potentially or
partly) useful genetic information is important and ought
not to be hindered by regulatory restrictions
Personal genome testing is to be considered an
informational or recreational product: consumer
information is sufficient to regulate the market and to
protect consumers from any risks
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moments within the testing process: pre-test informed
consent, post-test delivery of test results, and post-test
dealing with future (incidental) findings and changing
interpretations. There is a pressing need for well
thought-out models for valid informed consent and
information provision in the context of a lot of complex
and fluid information in non-targeted personal genome
testing.
Since personal genome testing is increasingly based on
highly accurate and reliable genome-wide SNP-scanning
technology and performed in high-quality laboratories,
the test characteristic analytical validity has moved away
from the centre of ELSI-discussions. Current debates are
focused rather on the clinical validity and utility of
genetic profiles for multifactorial diseases, which vary
strongly, but are likely to increase given time. Awareness
of the currently limited clinical validity is at the basis of
both conservative and liberal stances within the regula-
tory discourse: it is used either as an argument in favor
of stricter regulation, or as an argument against it.
The notion of clinical utility is challenged by personal
approaches towards the significance and usefulness of
genetic information. It is far from impossible that consu-
mers continue to attribute personal utility to genetic
information and pursue the acquisition of their genomic
data even after having been informed about the current
clinical limitations of genetic profiling for multifactorial
diseases. Standards of clinical utility that are used for
public health evaluations, however, need not be identical
to those used for individual valuations of utility.
As a consequence of their limited clinical validity, pre-
sent-day personal genome tests for multifactorial diseases
have a much lower potential for adverse psychological
effects than do clinical genetic tests for monogenic dis-
eases. Neither do they imply as many health risks, or
societal risks, such as discrimination, stigmatization and
misuse of genetic information by insurance companies or
employers. This holds true only on the condition that the
general public as well as other stake-holding parties are
sufficiently informed to understand the limitations to the
clinical validity and utility of genetic profiling for multi-
factorial diseases, and are willing to act accordingly. In
the future, as genetic profiles will attain more discrimina-
tive ability, both traditional psychological risks and con-
current health and societal risks will again be of concern
to the discourse on ELSI.
The applicability and the relevance of ELSI-issues to
the discourse on personal genome testing will fluctuate
with the analytical and clinical validity of genetic profiles,
with their clinical utility and with their being targeted or
non-targeted. Thus, consideration of test characteristics
is indispensible to any valuable ELSI-debate on personal
genome testing for multifactorial diseases.
Notes
1. To the knowledge of the authors, the company
Knome (pronounced as ‘know me’) is the only direct-to-
consumer provider of whole-genome sequencing that
offers (among other tests) risk profiling for multifactor-
ial diseases. See: http://www.knome.com/ (Accessed
June 13th, 2011)
2. See for example Navigenics at http://www.navi-
genics.com or Pathway Genomics at http://www.path-
way.com (Accessed June 13th, 2011)
3. See http://www.23andme.com (Accessed June 13th,
2011). Currently, the company 23andme offers risk profiles
for 195 diseases and other phenotypic traits, but the num-
ber of traits tested for increases monthly. The company
also provides ancestry and carrier status information.
While most other direct-to-consumer personal genome
testing companies are currently offering scans for no more
than a few dozen diseases, they are likely to expand their
services in the future rather than restrict them.
4. Most US-based companies collaborate with CLIA-
certified laboratories, see for example http://www.
knome.com (Accessed June 13th, 2011). With the Clini-
cal Laboratory Improvement Amendment (CLIA) of
1988, the US government has set quality standards for
all laboratory tests, ensuring their accuracy, reliability,
and timeliness.
5. The company 23andme states that it makes use of a
chip which demonstrates over 99.9% reproducibility:
“This means that if [the laboratory] ran the same DNA
a second time on a new chip, more than 99.9% of the
data would be the same compared to data from the first
run” https://www.23andme.com/you/faqwin/dataaccu-
racy/. (Accessed June 13th, 2011)
6. There are other diseases that are more promising
for predictive genetic profiling: SNPs have been found
to be associated with almost 3-fold risks for age-related
macular degeneration (AMD). Genetic profiles for AMD
have already been made available online (https://
www.23andme.com/health/Age-related-Macular-Degen-
eration/techreport/, http://www.arcticdx.com/ (Accessed
June 13th, 2011)). Relatively strong predictive abilities
such as those in genetic profiling for AMD are far from
typical for common multifactorial diseases.
7. The fluidity of test results depends in part on the clin-
ical validity of the existing profile: the higher that validity,
the less likely it will change with the advancement of
genetics research and the inclusion of additional markers.
8. The extent to which the problem of informed con-
sent is present, however, will depend on various aspects,
as it will be easier to effectively provide information, for
instance, if the amount of diseases tested for is smaller.
9. As these statements have been written before cur-
rent personal genome testing companies started to offer
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genome-wide non-targeted genetic profiling, it is not
self-evident that the terms “all genetic testing” in these
statements also include present-day commercial services.
10. See for example 23andme at http://www.23andme.
com or Navigenics at http://www.navigenics.com
(Accessed June 13th, 2011).
11. See https://www.23andme.com/health/Colorectal-
Cancer/ (Accessed June 13th, 2011)
12. Respondents were US cancer genetics professionals
involved in highly predictive genetic testing for familial
cancer syndromes. Respondents may be assumed to
consider the risk of genetic discrimination to be lower
in case of genetic profiling in the context of multifactor-
ial diseases.
13. It should be noted that misuse and abuse of
genetic risk information by employers or insurance
companies cannot be excluded completely, for employ-
ers and insurance companies are susceptible to misinter-
pretation of genetic test results, and to overstatement of
their significance.
14. See for example Pathway Genomics at http://www.
pathway.com (Accessed June 13th, 2011).
15. These studies have been conducted in the context
of genetic testing for highly predictive single-gene
makers, such as BRCA1 and BRCA2. Women had been
informed, for example, that genetic test results are often
inconclusive and that they are of unclear significance in
the absence of a family history of breast cancer [68,70].
As the results provided by most genetic profiling ser-
vices are much more uncertain, one would expect the
effect of disappointment found in these studies to be
increased for personal genome testing.
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